Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer

(2014) Hee Jin Lee et al.   BREAST CANCER RESEARCH AND TREATMENT

Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers

(2014) G. Di Caro et al.   CLINICAL CANCER RESEARCH

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

(2014) S. D. Brown et al.   GENOME RESEARCH

Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype

(2014) Mieke Van Bockstal et al.   VIRCHOWS ARCHIV

Characteristics of tertiary lymphoid structures in primary cancers

(2014) Jérémy Goc et al.   OncoImmunology

The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer

(2013) Z M A Mohammed et al.   BRITISH JOURNAL OF CANCER

Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer

(2013) A N Seo et al.   BRITISH JOURNAL OF CANCER

Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

(2013) Hee Jin Lee et al.   Journal of Breast Cancer

CD4+ follicular helper T cell infiltration predicts breast cancer survival

(2013) Chunyan Gu-Trantien et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin  -Producing Dendritic Cells in Human Breast Cancer

(2013) L. Martinet et al.   JOURNAL OF IMMUNOLOGY

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

(2013) Sherene Loi   OncoImmunology

The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer

(2012) Z MA Mohammed et al.   BRITISH JOURNAL OF CANCER

Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

(2012) Q. Wang et al.   CANCER RESEARCH

Increased lymphocytic infiltration in breast cancer correlated with molecular subtypes and HER2 gene amplification

(2012) Julia Y S Tsang et al.   HISTOPATHOLOGY

Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: Unusually high frequency of down-regulation in breast cancer tissues

(2012) Toshihiko Torigoe et al.   PATHOLOGY INTERNATIONAL

Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression

(2012) Masayuki Inoue et al.   OncoImmunology

Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer

(2011) L. Martinet et al.   CANCER RESEARCH

Vascular characterisation of triple negative breast carcinomas using dynamic MRI

(2011) Sonia P. Li et al.   EUROPEAN RADIOLOGY

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial

(2010) S E Pinder et al.   BRITISH JOURNAL OF CANCER

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

(2010) Teemu T. Junttila et al.   CANCER RESEARCH

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   Journal of Oncology Practice

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY